Glabellar Lines Clinical Trial
Official title:
Phase III, Randomised, Double Blind, Placebo Controlled and Open Label Phase Multicentre Study to Investigate the Efficacy and Safety of BTX-A-HAC NG in the Treatment of Moderate to Severe Glabellar Lines, and Assess the Long Term Efficacy and Safety of BTX-A-HAC NG Following Repeated Treatments in This Indication
The purpose of the protocol is to demonstrate the safety and the efficacy of a single injection of a new formulation of Clostridium Botulinum toxin type A haemagglutinin complex (BTX A HAC NG) to improve the appearance of moderate to severe glabellar lines (the lines between the eyebrows) and to assess the long term efficacy and safety of BTX-A-HAC NG after repeated injections.
This is a multicentre study conducted in two periods. Subjects will first be enrolled to enter the double blind (DB) period Cycle 1. Subjects who are eligible for retreatment will then be offered to enter open label (OL) Cycles 2 to 5 as DB roll-over subjects. Once recruitment of the DB period is complete, the study will enrol additional BTX-naïve subjects (hereafter referred to as OL de novo subjects) into the OL period Cycle 1. All OL de novo subjects who are eligible for retreatment will also be offered to enter OL Cycles 2 to 5. A total of 580 subjects (180 subjects randomised in the DB period and an additional 400 de novo subjects in the OL period) are planned to complete the study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04096326 -
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
|
Phase 2 | |
| Completed |
NCT02961673 -
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
|
Phase 1/Phase 2 | |
| Completed |
NCT01271452 -
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
|
Phase 4 | |
| Completed |
NCT05013424 -
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
|
Phase 2 | |
| Completed |
NCT01189760 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
| Completed |
NCT05100199 -
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
|
Phase 2 | |
| Completed |
NCT03721016 -
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT04157686 -
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
|
Phase 3 | |
| Completed |
NCT02353897 -
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
|
||
| Completed |
NCT03732833 -
MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT06212960 -
Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines
|
Phase 1 | |
| Completed |
NCT05089357 -
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
|
||
| Completed |
NCT00408785 -
A Study Of BOTOX For The Treatment Of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05380154 -
Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.
|
Phase 3 | |
| Completed |
NCT01224015 -
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
|
Phase 3 | |
| Completed |
NCT05248880 -
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
|
Phase 3 | |
| Completed |
NCT03216408 -
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines
|
Phase 3 | |
| Recruiting |
NCT06308198 -
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
|
Phase 3 | |
| Completed |
NCT05298449 -
Phase 2 of HU-045 in Glabellar Lines
|
Phase 2 | |
| Not yet recruiting |
NCT06246552 -
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
|
Phase 2 |